Accueil > Actualité
Actualite financiere : Actualite bourse

Roche: approval in spinal muscular atrophy

( - Swiss healthcare giant Roche has announced that the US FDA has approved its Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children two months of age and older.

Evrysdi showed "clinically significant" improvements in motor function in two clinical trials in people of various ages and disease severity levels, including SMA types 1, 2 and 3.

Copyright (c) 2020 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.